Quantum Healthcare Limited provided earnings guidance for the six months ended 30 June 2023. For the period, the Group is expecting to report a higher net loss for the six months ended 30 June 2023 ("HY2023") as compared to the six months ended 30 June 2022 ("HY2022"). The earnings guidance is based on a preliminary assessment of the Group's unaudited consolidated financial results for HY2023.

The reason for the higher net loss for HY2023 was mainly attributed to the significant legal expenses incurred for the arbitration involving TriReme Singapore Pte Ltd. and Quattro Vascular Pte Ltd. and InnoRa GMBH, which are non-operating in nature. For details on the foregoing arbitration, please refer to the separate update announcements made by the Company.